Daegu Catholic Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Eun Soo
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05175950: Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

Active, not recruiting
2
770
RoW
SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
Korea University Guro Hospital, Korean Center for Disease Control and Prevention
COVID-19 (Healthy Volunteers)
08/23
11/23
REVERSE-AR, NCT05212597: Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

Recruiting
2
100
RoW
Sacubitril-valsartan, Entresto, Amlodipine-losartan, Amosartan
Samsung Medical Center
Aortic Valve Insufficiency
12/23
12/24
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
SLOWH, NCT03845244: Weaning Protocol for High Flow Nasal Cannula Oxygen Therapy

Completed
N/A
100
RoW
Flow reduction first, FiO2 reduction first, Simultaneous (flow and FiO2) reduction
Seoul National University Hospital
High Flow Nasal Cannula, Respiratory Insufficiency
03/24
03/24
Reduction-TR, NCT05686616: SGLT2 Inhibitor for Severe Tricuspid Regurgitation

Recruiting
N/A
72
RoW
Dapagliflozin Propanediol Hydrate 12.3 mg, Forxiga Tablet 10mg
Samsung Medical Center
Tricuspid Regurgitation
04/24
03/25
EPICODE, NCT02193464: Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk

Recruiting
N/A
100
RoW
Kyungpook National University Hospital, Yeungnam University Hospital, Daegu Catholic University Medical Center, DongGuk University
Idiopathic Chronic Inflammatory Bowel Disease
12/25
12/26

Download Options